LA JOLLA, CA – May 12, 2025 – In a landmark development poised to redefine the treatment landscape for metabolic disorders, scientists at the Salk Institute have pinpointed a crucial group of proteins, known as estrogen-related receptors (ERRs), as indispensable regulators of energy metabolism and muscle function. Their groundbreaking study, published today in the prestigious journal Proceedings of the National Academy of Sciences, suggests that harnessing these receptors could unlock a powerful new therapeutic avenue for repairing compromised energy production and alleviating muscle fatigue across a spectrum of debilitating conditions.
The findings offer a beacon of hope for millions globally suffering from mitochondrial dysfunction, a pervasive cellular defect that undermines the body’s ability to convert food into usable energy. From rare genetic disorders to common age-related ailments and chronic diseases like cancer, multiple sclerosis (MS), heart disease, and dementia, impaired mitochondrial function contributes significantly to muscle weakness and profound fatigue. By identifying ERRs as direct orchestrators of mitochondrial health and activity, the Salk team has illuminated a promising pharmacological target that could restore vitality where it is most desperately needed.
Main Facts: A New Frontier in Metabolic Health
The core discovery from the Salk Institute reveals that estrogen-related receptors, particularly the alpha subtype (ERRα), are not merely passive players but active drivers in the critical process of mitochondrial biogenesis – the cellular mechanism by which new mitochondria are formed. These tiny, bean-shaped powerhouses are responsible for generating the vast majority of energy within our cells, a process especially vital in energy-intensive tissues like skeletal muscle. When muscles need more fuel, such as during exercise, ERRs step up, increasing both the number and efficiency of mitochondria.
The study unequivocally demonstrates that ERRα is essential for the muscle’s adaptive response to physical activity, a finding that holds profound implications. For individuals struggling with metabolic disorders or severe muscle weakness, the ability to exercise and naturally stimulate mitochondrial growth is often severely limited. The Salk research now proposes a pathway to pharmacologically mimic these exercise-induced benefits by activating ERRs, effectively turning on the body’s intrinsic energy production machinery without the need for strenuous physical exertion.
This scientific breakthrough offers a direct and actionable therapeutic strategy. Unlike previous targets, which often involved indirect mechanisms, ERRs are shown to bind directly to the DNA sequences that govern mitochondrial energy production, allowing for a more precise and potentially more effective drug development approach. The promise lies in developing drugs that can specifically boost ERR activity, thereby restoring energy supplies in patients with conditions ranging from muscular dystrophy to the generalized metabolic decline associated with aging.
Chronology: From Foundational Discoveries to Breakthrough Insight
The journey to this pivotal discovery is deeply rooted in decades of foundational research at the Salk Institute, particularly the pioneering work of senior author Ronald Evans.
The Genesis of Nuclear Hormone Receptors
The story truly begins in the 1980s, when Professor Ronald Evans, then a relatively young but ambitious researcher, led the landmark discovery of a novel family of proteins he named "nuclear hormone receptors." This discovery fundamentally reshaped our understanding of how hormones exert their effects on the body. These receptors, unlike those found on the cell surface, reside within the cell’s nucleus, where they act as molecular switches. Upon binding to specific hormones, they attach themselves directly to DNA, controlling the intricate dance of gene expression – turning genes "on" or "off" to regulate a myriad of biological processes, from development and metabolism to inflammation and reproduction. This monumental work laid the groundwork for understanding how many drugs, including those for cancer and diabetes, function.
Unveiling Estrogen-Related Receptors
Among the diverse branches of this nuclear hormone receptor family, Evans’ lab specifically identified estrogen-related receptors (ERRs) in 1988. Initially recognized for their structural similarity to classic estrogen receptors, their precise physiological function remained a captivating enigma for many years. However, early research by Evans’ team began to hint at their significant, albeit less understood, role in energy metabolism. Intriguingly, ERRs were observed to be highly abundant in tissues that demand substantial energy, such as the heart and the brain – organs where uninterrupted energy supply is absolutely critical for survival and function. This observation naturally piqued the researchers’ curiosity about their potential involvement in another high-energy demanding organ: skeletal muscle.
The Unmet Need: Addressing Mitochondrial Dysfunction
The human body’s reliance on efficient energy production cannot be overstated. At the heart of this process are mitochondria, the cellular organelles responsible for converting nutrients into adenosine triphosphate (ATP), the primary energy currency of the cell. This cellular-level metabolism is particularly paramount in muscle cells, which require an immense and continuous supply of fuel to power every movement, from a subtle twitch to a marathon sprint.
However, mitochondrial dysfunction is a widespread and devastating problem. Approximately 1 in 5,000 individuals are born with genetic defects that render their mitochondria dysfunctional from birth, leading to severe and often life-limiting conditions. Furthermore, countless others develop metabolic dysfunction later in life, a grim consequence of aging or an unwelcome companion to a growing list of chronic diseases. Conditions such as cancer, multiple sclerosis, heart disease, diabetes, and various forms of dementia are increasingly linked to impaired mitochondrial function, manifesting as profound fatigue, muscle weakness, and a general decline in physical and cognitive capabilities. The medical community has long grappled with the challenge of treating these complex and diverse manifestations of metabolic impairment, highlighting a critical unmet need for effective therapies.
Exercise: A Natural but Often Inaccessible Stimulus
It has long been understood that one of the most potent natural stimulants for improving mitochondrial health and function is exercise. When muscles are challenged, they respond by increasing mitochondrial biogenesis – essentially creating more energy factories – and enhancing the efficiency of existing ones. This adaptive response is fundamental to improving endurance, strength, and overall metabolic fitness.
However, this natural remedy presents a cruel paradox for those who need it most. For individuals afflicted with muscular dystrophies, chronic fatigue syndromes, advanced age, or severe metabolic disorders, the very act of exercising can be excruciating, impossible, or even detrimental. This inherent limitation has driven scientists to relentlessly search for alternative methods to trigger mitochondrial biogenesis and improve energy metabolism without requiring physical exertion. This is precisely where the Salk team’s research began to converge on the role of ERRs.
The Experimental Quest for a Pharmacological Solution
First author Weiwei Fan, a staff scientist in Evans’ lab, articulated the core hypothesis guiding their experimental design: "Mitochondria are our cells’ energy factories, so the more we exercise, the more mitochondria our muscles need. This got us thinking — if we could understand how exercise induces mitochondrial biogenesis, we might be able to target those same mechanisms pharmacologically to trigger this process in people who are too weak to exercise."
To systematically investigate the role of estrogen-related receptors in muscle cell metabolism, Fan and his colleagues embarked on a series of meticulous experiments using genetically modified mice. They specifically deleted the genes encoding three different forms of ERRs – alpha (ERRα), beta (ERRβ), and gamma (ERRγ) – within the muscle tissues of these mice. By observing the physiological consequences of these deletions, the researchers aimed to unravel the specific contributions of each receptor subtype to muscle energy production.
Their initial observations revealed a complex interplay between the different ERR subtypes. While ERRα was found to be the most abundant receptor in muscle tissue, its isolated deletion had surprisingly mild impacts under normal, unstressed conditions. This indicated a potential compensatory mechanism. Indeed, the researchers discovered that the gamma receptor (ERRγ), despite constituting only about 4% of the total ERR population, possessed a remarkable capacity to compensate for the loss of ERRα, maintaining muscle mitochondrial function. However, the true importance of ERRα became starkly evident when both the alpha and gamma types were simultaneously deleted. This dual knockout resulted in severe impairments in muscle mitochondrial activity, significantly altering their shape, size, and overall functional capacity.
Unmasking ERRα’s Indispensable Role in Exercise Adaptation
The lingering question was why ERRα, the most abundant subtype, seemed to have such a profound redundancy or compensatory mechanism under normal conditions. The team hypothesized that ERRα’s true indispensability would only be revealed under conditions of high metabolic demand, specifically during exercise, when muscles need to adapt and grow their mitochondrial machinery.
To test this hypothesis, the researchers put their genetically modified mice through a regimen of exercise on mechanical wheels. This exercise challenge was designed to robustly trigger mitochondrial biogenesis, allowing the scientists to precisely assess whether ERRα was indeed a critical component of this adaptive process. The results were striking: the loss of ERRα alone completely blocked exercise-induced mitochondrial biogenesis. This definitive finding solidified ERRα’s position as a crucial, non-redundant driver of the muscle’s ability to respond to and benefit from physical activity.
The PGC1α Connection: A Direct Therapeutic Target Emerges
Prior research had established another protein, PGC1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha), as a "master regulator" of mitochondria throughout the body. PGC1α is known to orchestrate many aspects of mitochondrial biogenesis and function. However, PGC1α presents a significant challenge for therapeutic drug development. Unlike nuclear hormone receptors such as ERRs, PGC1α cannot bind directly to DNA to activate genes. Instead, it acts as a co-activator, relying on partner proteins to physically interact with the genome and execute its regulatory commands. This indirect mode of action makes PGC1α a more elusive and difficult target for pharmacological intervention.
The Salk team’s pivotal discovery was uncovering the direct functional link between PGC1α and ERRα. When Evans’ lab examined muscle cells after exercise, they found that PGC1α was actively partnering with ERRα to drive mitochondrial biogenesis. Crucially, and unlike PGC1α, ERRα can bind directly to the specific genetic sequences that control mitochondrial energy production, effectively turning these critical genes "on." This direct binding capability positions ERRα as a far more accessible and promising target for developing drugs that can precisely enhance muscle mitochondrial performance.
Supporting Data: The Intricacies of Cellular Energy and Receptor Function
The elegant precision of the Salk study lies in its detailed illumination of how estrogen-related receptors operate at a fundamental cellular and molecular level to govern energy metabolism.
Mitochondria: The Cell’s Power Plants
To fully appreciate the significance of this research, it’s essential to understand the role of mitochondria. Often referred to as the "powerhouses of the cell," mitochondria are membrane-bound organelles found in virtually all eukaryotic cells. Their primary function is cellular respiration, a complex metabolic pathway that converts nutrients like glucose and fatty acids into ATP. This process requires a continuous supply of oxygen and produces carbon dioxide as a byproduct. Without efficient mitochondrial function, cells cannot generate enough energy to perform their vital tasks, leading to cellular dysfunction, tissue damage, and ultimately, systemic disease. Muscle cells, in particular, are densely packed with mitochondria, reflecting their enormous energy demands for contraction and movement.
The Prevalence and Impact of Mitochondrial Dysfunction
The scope of mitochondrial dysfunction extends far beyond rare genetic diseases. It is increasingly recognized as a central contributor to the pathogenesis of numerous common and debilitating conditions:
- Aging: As we age, mitochondrial function often declines, contributing to age-related muscle weakness (sarcopenia), fatigue, and a reduced capacity for physical activity.
- Cancer: Dysfunctional mitochondria can alter cellular metabolism, promoting cancer cell growth and resistance to therapy.
- Multiple Sclerosis (MS): Mitochondrial damage is implicated in the neurodegeneration and chronic fatigue experienced by MS patients.
- Heart Disease: Cardiac muscle is highly energy-dependent, and mitochondrial dysfunction can lead to heart failure and other cardiovascular ailments.
- Dementia: Growing evidence links impaired mitochondrial function in brain cells to neurodegenerative diseases like Alzheimer’s and Parkinson’s, contributing to cognitive decline.
Given this widespread impact, finding effective ways to improve mitochondrial health is a major objective in biomedical research.
Estrogen-Related Receptors (ERRs): Structure and Function
Estrogen-related receptors are a fascinating subgroup within the nuclear hormone receptor superfamily. Despite their name and structural resemblance to classic estrogen receptors (which bind to the hormone estrogen), ERRs do not bind estrogen. Instead, they are constitutively active or bind to other, as-yet-unidentified endogenous ligands. The three subtypes (ERRα, ERRβ, ERRγ) exhibit distinct tissue distribution patterns and functional roles, though they often overlap and can compensate for each other, as observed in this study.
Their critical function revolves around regulating the expression of genes involved in various metabolic pathways, particularly those related to mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation – the core processes of energy production. The Salk study specifically highlighted ERRα’s pivotal role in driving the transcriptional programs necessary for muscle adaptation to exercise.
The Specifics of the Mouse Model Findings
The detailed results from the mouse studies provided granular evidence:
- ERRα Abundance and Compensation: The finding that ERRα is the most abundant but its singular loss has mild effects initially, points to the sophisticated redundancy within the ERR system. The 4% contribution of ERRγ to compensation underscores its potent regulatory capacity despite its lower expression levels.
- Synergistic Action: The severe impairment observed when both ERRα and ERRγ were deleted highlights their synergistic action. While ERRα appears to be the primary driver under stress (like exercise), ERRγ plays an important baseline role and can step in during normal conditions.
- Exercise-Induced Biogenesis Blockade: The complete blockage of exercise-induced mitochondrial biogenesis upon ERRα deletion is the most compelling evidence of its indispensability. This demonstrates that ERRα is not just a participant but a critical mediator of the muscle’s adaptive response to increased energy demand.
By elucidating this hierarchical and cooperative function among ERR subtypes, the Salk team has provided a detailed molecular map for future therapeutic interventions, suggesting that targeting specific ERR subtypes or combinations thereof might yield the most effective outcomes.
Official Responses: Expert Perspectives on a Promising Breakthrough
The Salk Institute’s findings have been met with significant enthusiasm from the research team, underscoring the potential impact of their work.
Professor Ronald Evans, a titan in the field of molecular biology and the senior author of the study, expressed the profound significance of this discovery: "Estrogen-related receptors look a lot like classic estrogen receptors, but their function has been much less understood. Our lab discovered estrogen-related receptors in 1988 and was one of the first to recognize their role in energy metabolism. Now we’ve learned that estrogen-related receptors are indispensable drivers of mitochondrial growth and activity in our muscles. This makes them a really promising target to treat muscle weakness and fatigue in many different diseases that involve metabolic dysfunction." His remarks highlight the culmination of decades of research, evolving from initial identification to a deep understanding of their critical regulatory functions. The emphasis on "indispensable" underlines the non-redundant and central role ERRs play, particularly in adaptive physiological responses.
Weiwei Fan, the study’s first author, echoed this optimism, elaborating on the broader implications: "Our findings suggest that activating estrogen-related receptors could not only help fuel people’s muscles, but it could also have other beneficial effects across the whole body. Improving mitochondrial function and energy metabolism could help strengthen many different organ systems, including the brain and heart." This perspective extends the potential therapeutic reach beyond skeletal muscle, envisioning systemic benefits that could profoundly improve the quality of life for patients with a wide array of conditions. The interconnectedness of organ systems means that a boost in fundamental energy production in one area can cascade into improved function elsewhere.
The scientific community broadly recognizes the immense challenge of treating metabolic disorders effectively. The current therapeutic landscape often provides symptomatic relief rather than addressing the root cause of mitochondrial dysfunction. The Salk team’s identification of a direct, targetable mechanism like ERR activation represents a significant leap forward. It offers a new paradigm, moving towards therapies that can fundamentally restore cellular energy balance. Experts in the field, while cautiously optimistic about the long road of drug development ahead, acknowledge that discovering such a direct and powerful regulatory switch for mitochondrial biogenesis is a rare and invaluable scientific achievement. The clarity of ERRα’s role in coordinating with PGC1α and directly influencing gene expression makes it an exceptionally attractive candidate for pharmaceutical development.
Implications: Reshaping the Future of Metabolic Therapies
The Salk Institute’s discovery holds transformative potential, opening up an exciting new chapter in the fight against metabolic disorders and age-related decline.
A New Therapeutic Horizon for Metabolic Disorders
The most immediate and profound implication of this research is the potential for developing a new class of drugs specifically designed to activate estrogen-related receptors. Such drugs could serve as powerful tools to restore energy supplies in individuals suffering from conditions characterized by muscle weakness and fatigue due to mitochondrial dysfunction. Muscular dystrophy, a group of genetic diseases causing progressive weakness and loss of muscle mass, is explicitly mentioned as a key target. For patients whose muscles are deteriorating, a therapy that can stimulate mitochondrial growth and enhance energy output could significantly slow disease progression, improve muscle function, and enhance overall mobility and quality of life. Beyond muscular dystrophy, the implications extend to chronic fatigue syndrome, sarcopenia in the elderly, and even cachexia associated with cancer.
Systemic Benefits Beyond Muscle Tissue
As Fan highlighted, the benefits of improved mitochondrial function are unlikely to be confined solely to skeletal muscles. Given that ERRs are found in other high-energy demand organs like the heart and brain, and that mitochondrial dysfunction underlies many systemic diseases, activating these receptors could have widespread positive effects. Enhancing energy metabolism could translate into improved cardiac function in patients with heart failure, bolster cognitive function in individuals with neurodegenerative diseases, and even improve overall cellular resilience against various forms of stress and damage. This suggests that ERR-targeting drugs could offer a holistic approach to treating conditions that manifest across multiple organ systems.
Advancing Drug Development Strategies
The direct gene-binding capability of ERRα makes it a particularly attractive drug target. Unlike co-activators like PGC1α, which require complex interactions with other proteins to exert their effects, ERRα’s direct interaction with DNA simplifies the pharmacological challenge. This clarity in mechanism could accelerate the drug discovery and development process, potentially leading to more potent, specific, and safer therapeutic agents. The research provides a clear molecular handle for pharmaceutical companies to design compounds that can precisely modulate ERR activity.
Future Research Directions
While this study marks a significant milestone, it also paves the way for extensive future research. The Salk team plans to delve deeper into the nuanced functions and regulatory mechanisms of both alpha- and gamma-type receptors. Understanding how these different subtypes interact, compensate, and respond to various physiological cues will be crucial for developing highly targeted and effective therapies. For instance, future studies might explore:
- The precise identification of natural ligands or modulators for ERRs.
- The differential roles of ERRα and ERRγ in various muscle types and under different metabolic stresses.
- The long-term effects and safety profiles of ERR activation in animal models.
- The potential for combination therapies that target ERRs alongside other metabolic pathways.
This continued exploration promises to yield further insights into mitochondrial biology and potentially uncover additional therapeutic targets, building upon the foundational knowledge established by this latest Salk Institute breakthrough.
The work, supported by a consortium of esteemed institutions including the National Institutes of Health, the Department of the Navy, the Larry L. Hillblom Foundation, Inc., the Wu Tsai Human Performance Alliance, the Henry L. Guenther Foundation, and the Waitt Foundation, underscores the collaborative and well-resourced effort behind this pivotal scientific advance. With this discovery, the Salk Institute has not only deepened our understanding of cellular energy regulation but has also ignited a new wave of hope for millions battling the pervasive challenges of metabolic dysfunction.
About the Author
